As guidance changes and clinical trials modernize, the way that companies think about quality and risk in the design and conduct of a study must evolve as well. While RBQM has been widely adopted among midsize and large biopharmaceutical companies, challenges remain in reconciling risk-based approaches with traditional monitoring. SCOPE’s Clinical Quality and Risk Management program will provide an opportunity for clinical operations leaders to exchange best practices, case studies, and high-level strategies for integrating a risk-based approach throughout the clinical research cycle and across functional areas. The Central and Remote Monitoring track will highlight some of the challenges of monitoring an ever-increasing dataset and strategies for maximizing the benefits of having a real-time view of study performance.